Amarantus Bioscience Holdings Inc (AMBS)

[Riskreturn168]

On the topic of up listing in the CC, here is what Gerald had to say about catalysts that will help make it happen:

It’s important to note that we still had these warrants outstanding when we heard certain price milestones, we can enforce exercise delivering additional cash to the company which will improve our position to be able to uplift without additional significant dilution. So, we think we’ve got all the tools in the tool shed to make it happen, and we just intend to be opportunistic around catalytic events related to LymPro, events related with Eltoprazine, you know, we’re going to be dialoguing with the FDA on Eltoprazine about trial design, breakthrough, fast track, etc., etc., as we get ready for this clinical trial. And then obviously MANF, there are a number of possibilities there. So, we think we can improve shareholder value and we’ve got, certainly from a financial engineering standpoint some very good ideas about other things that we can do to really reward our shareholders.

I wonder what Gerald was referring to regarding "financial engineering" that can "really reward our shareholders?" That sounds like using a share buyback program or something like that to improve shareholder value.

Does anyone have any thoughts on what Gerald might have meant?